MetaCap

Lipocine Inc. (LPCN)

NASDAQ: LPCNHealth CareBiotechnology: Pharmaceutical PreparationsUSD

1.48-0.02 (-1.33%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

LPCN stock chart

Technical analysis

Key statistics

All statistics
Market cap
$16.39M
EPS (TTM)
-$1.32
52-week range
1.36 – 12.37
Day range
1.43 – 1.55
Volume / Avg
215.73K / 1.84M
Beta
—

52-week range

$1.36$12.37

LPCN stock today

Shares of Lipocine (LPCN) finished lower on Nov 20 at $1.48, a drop of 1.33% or $0.02 per share, versus the S&P 500's 3.70% decline. Trading was light, with 215.73K shares changing hands, about 12% of the average daily volume. Shares are 88.0% below their 52-week high of $12.37, set on Jan 15, 2026 and 8.8% above the 52-week low of $1.36, near the bottom of the past year's range.

LPCN is down 81.6% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 53.2%. Lipocine has posted a net loss over the last twelve months (EPS of -$1.32), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Lipocine

Company profile

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. The company offers TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. It also develops LPCN 1154 (BRLIZIO), an oral neuro-steroid in a Phase 3 pivotal trial for postpartum depression; LPCN 1148, a prodrug of testosterone and testosterone laurate that has completed a Phase 2 trial for the management of decompensated cirrhosis; LPCN 1107, an oral hydroxy progesterone caproate product that has completed a Phase 2 trial for the prevention of recurrent preterm birth; LPCN 1144, an oral prodrug of bioidentical testosterone that has completed a Phase 2 trial for pre-cirrhotic non-alcoholic steatohepatitis; and LPCN 2401, an oral formulation comprising a proprietary anabolic androgen receptor agonist that is in a Phase 2 trial to manage incretin mimetic use in obesity management.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Mahesh V. Patel Ph.D.
Headquarters
Salt Lake City, UT
Employees
14

Financial highlights

Full financials

In fiscal 2025, Lipocine generated $2.0 million in revenue, down 82.3% from fiscal 2024, its first annual decline since 2023. Lipocine reported a net loss of $9.6 million, compared with net income of $8,352 a year earlier. Operating margin was -524.7%.

Lipocine annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$1.98M$11.20M$-2.85M$500.00K$16.14M
Growth-82.35%+492.80%-670.16%-96.90%—
Net income$-9.63M$8.35K$-16.35M$-10.76M$-634.40K
EPS (diluted)$-1.69—$-3.14$-2.15$-0.01

Analyst forecast

Forecast

Consensus (2 analysts)

none

Avg. price target

$5.00+237.84%

  • Strong buy 0
  • Buy 1
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $4.00High $6.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$-0.08 vs $-0.39
Surprise
+79.49%

LPCN news

All LPCN news

Lipocine peers

Health Care sector
LPCN peer companies
CompanyPrice% ChgMarket capCompare
SHPHShuttle Pharmaceuticals Holdings Inc.3.49-10.51%$16.63Mvs LPCN
AKTXAkari Therapeutics plc ADS7.18+7.00%$16.70Mvs LPCN
ATOSAtossa Therapeutics Inc.1.60-8.86%$15.92Mvs LPCN
PBMPsyence Biomedical Ltd.2.97+3.85%$15.80Mvs LPCN
QNRXQuoin Pharmaceuticals Ltd. ADR3.28-2.35%$15.76Mvs LPCN
KTTAPasithea Therapeutics Corp.0.4787-0.48%$17.59Mvs LPCN
MRKRMarker Therapeutics Inc.1.09-17.42%$18.17Mvs LPCN
CELUCelularity Inc. Class A0.463-1.05%$15.02Mvs LPCN

Indexes, lists and sector

Lipocine stock FAQ

What is Lipocine's stock price today?

LPCN last traded at $1.48 as of Nov 20, 4:00 PM EST, down 1.33% on the day. Prices are delayed at least 15 minutes.

Does Lipocine pay a dividend?

No. Lipocine does not currently pay a regular cash dividend.

Who is Lipocine's CEO?

Dr. Mahesh V. Patel Ph.D. is the chief executive officer of Lipocine Inc., which has about 14 employees.

Has LPCN ever split its stock?

Yes. The most recent LPCN stock split was a 1-for-17 split on May 12, 2023.

What is the LPCN 52-week high?

The 52-week high for LPCN is $12.37 and the 52-week low is $1.36. The stock is currently 88.0% below its high.

Compare LPCN